predictors of long-term fatal cardiovascular events after planned percutaneous coronary interventions

Aim. To evaluate the frequency and identify predictors of long­term fatal cardiovascular events (CVE) after planned percutaneous coronary interventions (PCI).

Material and methods. We conducted a retrospective study that included 150 patients who underwent planned endovascular intervention on the coronary arteries. Outcomes of interventions were assessed 6 years after the PCI, by analyzing medical records and telephone interviews. The primary endpoint of the study was cardiovascular­related death.

Results. Fatal CVE were recorded in 10,6% of patients. A statistically significant relationship was found between the development of fatal CVE in the long­term period after planned PCI and the presence of initial chronic obstructive pulmonary disease in patients (OR=12,3; CI (3,6­41,5); р<0,001), atrial fibrillation (OR=5,1; CI (1,6­16,3); p=0,003), diabetes mellitus (OR=3,2; CI (1,1­9,8); p=0,032), acute cerebrovascular accident (OR=8,6; CI (2,0­36,4); p=0,001); any clinical complications of interventions (OR=3,1; CI (1,1­9,0); p=0,028), taking of antiarrhythmic drugs (OR=5,9; CI (1,3­27,4); p=0,012), statins taking at the time of PCI (OR=0,3; CI (0,1­0,8); p=0,013). According to the results of the ROC­analysis, the most significant predictor of fatal CVE in the long­term period was erythrocyte sedimentation rate more than 14,5 mm/h (AUC=0,677; CI (0,507­0,835); p=0,027). According to 6­year observation, Kaplan­Meier curves showed a significant effect of multifocal atherosclerosis, acute periprocedural kidney injury and heart rhythm disorders recorded during PCI, on the incidence of long­term fatal CVE.

Conclusion. A statistically significant relationship between the development of fatal CVE in the long­term period after planned PCI and the presence of initial comorbid pathology in patients (chronic obstructive pulmonary disease, atrial fibrillation, diabetes mellitus, multifocal atherosclerosis, acute cerebrovascular accident), erythrocyte sedimentation rate more than 14,5 mm/h, concomitant drug therapy at the time of the intervention (taking of antiarrhythmic drugs, statins). Significant predictors of adverse long­term outcome after planned endovascular myocardial revascularization were clinical complications of PCI, recorded during the hospital period, especially acute periprocedural kidney injury and heart rhythm disorders.

1. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016; 37(29):2315-2381. DOI: 10.1093/eurheartj/ehw106.

2. Kaasenbrood L, Boekholdt SM, van der Graaf Y et al. Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation. 2016; 134(19):1419-1429. DOI: 10.1161/CIRCULATIONAHA.116.021314.

3. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)1; European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Guidelines on myocardial revascularization Eur. Heart J 2010; 31:2501–2555. DOI: 10.1093/eurheartj/ehq277.

4. Luscher TF, Obeid S. From Eisenhower’s heart attack to modern management: a true success story! Eur Heart J 2017; 38:3066–3069. DOI: 10.1093/eurheartj/ehx569.

5. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503–1516. DOI: 10.1056/NEJMoa070829.

6. Windecker S, Stortecky S, Stefanini GG, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ 2014; 348:g3859. DOI: 10.1136/bmj.g3859.

7. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2018; 391:31–40. DOI: 10.1016/S0140-6736(17)32714-9.

8. Chaitman BR, Mori Brooks M, Fox K, Luscher TF. ORBITA revisited: what it really means and what it does not? Eur Heart J 2018; 39:963–965.

9. VNOK. Diagnosis and treatment of stable angina. Russian recommendation (second revision). Cardiovascular therapy and prevention 2008; 7 (6): 4:1-28. Russian (ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика 2008; 7(6): 4:1–28).

10. Taniwaki M, Windecker S, Zaugg S, et al. The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J 2015; 36:2167–2176. DOI: 10.1093/eurheartj/ehv227.

11. Doyle B, Rihal CS, O’Sullivan CJ, et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 2007; 116:2391–2398. DOI: 10.1161/CIRCULATIONAHA.107.707331.

12. Raber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012; 125:1110–1121. DOI: 10.1161/CIRCULATIONAHA.111.058560.

13. Yamaji K, Kimura T, Morimoto T, et al. Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. Circ Cardiovasc Interv 2010; 3:468–475. DOI: 10.1161/CIRCINTERVENTIONS.110.958249.

14. Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011; 123:2819–2828. DOI: 10.1161/CIRCULATIONAHA.110.004762.

15. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381:629–638. DOI: 10.1016/S0140-6736(13)60141-5.

16. Mauri L, Kereiakes DJ, Yeh RW, et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371:2155–2166. DOI: 10.1056/NEJMoa1409312.

17. Yeh RW, Secemsky EA, Kereiakes DJ, et al. DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016; 315:1735–1749. DOI: 10.1001/jama.2016.3775.

18. Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389:1025–1034. DOI: 10.1016/S0140-6736(17)30397-5.

19. Vershinina EO, Repin AN. Acute effects of loading doses of statins at the elective percutaneous coronary interventions. Complex Issues of Cardiovascular Diseases 2017; 6(S4):16. Russian

20. Lam CSP, Gamble GD, Ling LH, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018 Jan 29; 0: 1–11. DOI: 10.1093/eurheartj/ehy005.

21. MacKenzie TA, Malenka DJ, Olmstead EM, et al. Prediction of survival after coronary revascularization: modeling short-term, mid-term, and long-term survival. Ann Thorac Surg 2009; 87:463–72. DOI: 10.1016/j.athoracsur.2008.09.042.

22. Wilson PW, D’Agostino R Sr, Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med 2012;125:695–703.

23. Vershininа EO, Repin AN, Ryabova TR. The impact of multifocal atherosclerosis on the early and late outcomes of elective endovascular treatment of ischemic heart disease. The Siberian Medical Journal (Tomsk) 2014; 29(3):87-93. Russian

24. Vershininа EO, Repin AN. Сontrast-induced acute kidney injury in a planned endovascular interventions on the coronary arteries. Klinicheskaya meditsina 2017; 95(12):1086-1093. Russian

25. Kleber ME, Koller L, Goliasch G, et al. Von Willebrand factor improves risk prediction in addition to N-terminal pro–B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction. Circ Heart Fail 2015; 8: 25–32.

26. Koller L, Kleber M, Goliasch G, et al. C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction. Eur J Heart Fail 2014; 16: 758–766. DOI: 10.1002/ejhf.104.

27. Gaggin HK, Bhardwaj A, Belcher A, et al. Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. IJC of Metabolic & Endocrine 2014; 5:11–18. DOI: 10.1016/j.ijcme.2014.08.005.

28. Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010; 303:1610–6. DOI: 10.1001/jama.2010.461.

29. Garg S, Sarno G, Garcia-Garcia HM, et al. A new tool for the risk stratification of patients with complex coronary artery disease: the Clinical SYNTAX Score 1. Circ Cardiovasc Interv 2010; 3:317–26. DOI: 10.1161/CIRCINTERVENTIONS.109.914051.